Targeting B7-H3 in patients with metastatic triple-negative breast cancer and brain metastases: an opportunity to “revive” immunotherapy as a treatment strategy?
Approximately one-third of patients with metastatic triple-negative breast cancer (TNBC) develop brain metastases during their lifetime. Notably, up to 90% of TNBC brain metastases express B7-H3, a molecule that contributes to an immunosuppressive mic…